PTAB/USPTO Update - October 2023

PTAB/USPTO Update - October 2023

Client Alert

Authors

USPTO News

Notices, Guidance, and Requests

Final Rules

  • There are no new final rules.

Interim Rules

  • There are no new interim rules.

Proposed Rules

  • There are no new proposed rules

Proposed Legislation

  • Medication Affordability and Patent Integrity Act (bill introduced by Representatives Ann M. Kuster, Diana Harshbarger on September 13, 2023 “[t]o require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office.”)

  • Prohibiting Adversarial Patents Act of 2023 (bill introduced on September 14, 2023 “[t]o amend title 35, United State Code, to require the Director of the United States Patent and Trademark Office to require disclosures in patent applications regarding ties to the People’s Republic of China and other foreign adversaries, and for other purposes.”)

PTAB Decisions

  • New Precedential PTAB Decisions 

    • There are no new informative PTAB decisions.

  • New Informative PTAB Decisions 

    • There are no new informative PTAB decisions.

  • Director Review Decisions 

    • There are no new director review decisions.

Authors

More From This Series

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.